Global Glioblastoma Multiforme Market - 2025 -2033
Global Glioblastoma Multiforme Market: Industry Outlook
The global glioblastoma multiforme market reached US$ 2.68 billion in 2023, with a rise to US$ 2.92 billion in 2024, and is expected to reach US$ 6.81 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025–2033.
The glioblastoma multiforme market is experiencing steady growth, driven by the rising global incidence of brain tumors and increased awareness of neurological health. The market is further supported by advancements in oncology research, particularly in immunotherapy, targeted drug delivery, and tumor-treating technologies. Innovations such as tumor treating fields (TTFields), next-generation chemotherapeutics, and personalized medicine approaches are enhancing treatment efficacy and extending survival outcomes. Additionally, growing investment in clinical trials, faster regulatory pathways like Orphan Drug and Breakthrough Therapy designations, and improved diagnostic imaging have contributed to early detection and more aggressive treatment strategies.
Key Market Trends & Insights
Driver: Rising Incidence of Glioblastoma Multiforme
The rising incidence of glioblastoma multiforme (GBM) is expected to significantly drive the growth of the GBM market, as increasing case numbers create a greater demand for effective diagnosis and treatment options. Recent epidemiological data indicate a steady rise in GBM diagnoses globally, partly due to improved diagnostic imaging techniques and increased awareness among healthcare professionals. For instance, according to the report by the National Institute of Health in 2025, Glioblastoma is the most common and lethal primary malignant brain tumor in adults, accounting for approximately 45–50% of all primary brain cancers. Its annual incidence is estimated at 3–5 cases per 100,000 individuals globally, with slightly higher rates observed in developed countries.
For instance, the Central Brain Tumor Registry of the United States (CBTRUS) reported an upward trend in GBM incidence over the past decade, especially among older adults. More than 13,000 Americans are diagnosed with GBM every year. This growing patient population is fueling the need for advanced therapies, including targeted drugs, immunotherapies, and novel treatment modalities like tumor treating fields (TTFields). Furthermore, ongoing clinical trials and regulatory approvals for new GBM treatments reflect the urgent demand to address this aggressive cancer. As more patients seek personalized and effective treatment solutions, the expanding prevalence of GBM will continue to be a key driver propelling market growth globally..
Restraint: Limited Treatment Efficacy and High Recurrence
Limited treatment efficacy and high recurrence rates are significant challenges expected to hinder the growth of the glioblastoma multiforme (GBM) market. Despite advances in surgery, chemotherapy, and radiation, GBM remains one of the most aggressive and treatment-resistant brain cancers, with standard therapies often providing only modest survival benefits. The tumor’s highly invasive nature and ability to develop resistance lead to frequent recurrences, making long-term disease management difficult. This results in high unmet medical needs and patient mortality, which can discourage investment and slow market expansion.
Segmentation Analysis
The glioblastoma multiforme market is segmented by treatment type, drugs, end-user, and region.
Treatment Type-The radiation therapy segment is estimated to have 39.7% of the glioblastoma multiforme market share.
Radiation therapy remains a cornerstone in the treatment of glioblastoma multiforme, serving as the dominant segment in the market due to its established efficacy in managing this aggressive brain cancer. Standard treatment typically involves surgical resection followed by adjuvant radiation therapy to target residual tumor cells. Recent advancements have enhanced the precision and effectiveness of radiation therapy. For instance, the integration of nanomedicine with proton and X-ray radiotherapy has shown promise in improving dose precision and radiosensitization, potentially overcoming the challenges posed by the blood-brain barrier and tumor microenvironment.
Additionally, the development of predictive digital twins for optimizing patient-specific radiotherapy regimens under uncertainty has been proposed, aiming to personalize treatment plans and improve outcomes. These innovations underscore the continued relevance and advancement of radiation therapy in the GBM treatment landscape.
Geographical Shares
The North America glioblastoma multiforme market was valued at 37.20% market share in 2024
North America holds a commanding position in the global glioblastoma multiforme (GBM) market, accounting for approximately 37.2% of the market share in 2024. This leadership is driven by several critical factors, including a robust and well-established healthcare infrastructure, widespread access to cutting-edge diagnostic and therapeutic technologies, and significant investments in research and development. The high incidence rate of GBM in the region further fuels demand for innovative treatments.
Moreover, government initiatives, such as the U.S. Department of Defense’s Glioblastoma Research Program (GBMRP), which received over $10 million in funding in 2024, have accelerated the development of new therapies. The region also benefits from a high concentration of pharmaceutical and biotech companies conducting advanced clinical trials, such as Gilead Sciences’ promising CAR-T cell therapy trials for recurrent GBM, which have demonstrated encouraging tumor response rates. These combined factors create a conducive environment for the rapid adoption of novel therapies, ensuring North America maintains its dominant market position through the forecast period.
The Asia-Pacific glioblastoma multiforme market was valued at 18.60% market share in 2024
The Asia-Pacific region is emerging as the fastest-growing market for glioblastoma multiforme treatments. This growth is driven by multiple factors, including rising incidence rates of GBM in populous countries such as China and India, expanding healthcare infrastructure, and increasing awareness of brain cancers among healthcare providers and patients.
Asia-Pacific has seen an upsurge in international collaborations for clinical research, accelerating the development and approval of innovative therapies tailored to the region’s diverse population. Enhanced diagnostic capabilities and growing adoption of advanced treatment modalities, including immunotherapies and targeted therapies, further fuel the region’s rapid market expansion. These dynamics collectively position Asia-Pacific as a critical growth driver in the global GBM market landscape.
Competitive Landscape
The major players in the glioblastoma multiforme market include Genentech (Roche), Pfizer Inc., Amgen Inc., Merck & Co., Inc., VBI Vaccines Inc. and Starlight Therapeutics, among others.
Genentech: Genentech is a prominent leader in the glioblastoma multiforme market, renowned for its innovative approach to developing targeted therapies and immuno-oncology treatments. The company’s flagship product, Avastin (bevacizumab), is widely used for managing GBM by inhibiting tumor blood vessel growth, helping to slow disease progression. Genentech continuously invests in advanced research and clinical trials to enhance treatment efficacy and explore combination therapies, reinforcing its position as a key player in the GBM market. Their commitment to cutting-edge science and patient-centric solutions ensures sustained growth and a strong global presence in the fight against glioblastoma.
Key Developments:
The global glioblastoma multiforme market reached US$ 2.68 billion in 2023, with a rise to US$ 2.92 billion in 2024, and is expected to reach US$ 6.81 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025–2033.
The glioblastoma multiforme market is experiencing steady growth, driven by the rising global incidence of brain tumors and increased awareness of neurological health. The market is further supported by advancements in oncology research, particularly in immunotherapy, targeted drug delivery, and tumor-treating technologies. Innovations such as tumor treating fields (TTFields), next-generation chemotherapeutics, and personalized medicine approaches are enhancing treatment efficacy and extending survival outcomes. Additionally, growing investment in clinical trials, faster regulatory pathways like Orphan Drug and Breakthrough Therapy designations, and improved diagnostic imaging have contributed to early detection and more aggressive treatment strategies.
Key Market Trends & Insights
- North America accounted for approximately 37.2% of the global glioblastoma multiforme market in 2024 and is expected to maintain its leading position throughout the forecast period. This dominance is driven by advanced healthcare infrastructure, substantial R&D investments, early adoption of innovative therapies such as tumor treating fields (TTFields) and immunotherapies, and strong regulatory support facilitating faster approvals.
- Asia-Pacific is projected to be the fastest-growing region, propelled by expanding healthcare access, increasing incidence of brain tumors, growing awareness of neurological diseases, and rising government initiatives to improve cancer care. Rapid economic development, increasing availability of diagnostic tools, and enhanced clinical trial activities further fuel market expansion in this region.
- Targeted therapies and personalized medicine approaches are gaining momentum as the dominant treatment segments, favored for their potential to improve survival outcomes and reduce side effects compared to conventional therapies.
- 2024 Market Size: US$ 2.92 Billion
- 2033 Projected Market Size: US$ 6.81 Billion
- CAGR (2025–2033): 9.6%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Driver: Rising Incidence of Glioblastoma Multiforme
The rising incidence of glioblastoma multiforme (GBM) is expected to significantly drive the growth of the GBM market, as increasing case numbers create a greater demand for effective diagnosis and treatment options. Recent epidemiological data indicate a steady rise in GBM diagnoses globally, partly due to improved diagnostic imaging techniques and increased awareness among healthcare professionals. For instance, according to the report by the National Institute of Health in 2025, Glioblastoma is the most common and lethal primary malignant brain tumor in adults, accounting for approximately 45–50% of all primary brain cancers. Its annual incidence is estimated at 3–5 cases per 100,000 individuals globally, with slightly higher rates observed in developed countries.
For instance, the Central Brain Tumor Registry of the United States (CBTRUS) reported an upward trend in GBM incidence over the past decade, especially among older adults. More than 13,000 Americans are diagnosed with GBM every year. This growing patient population is fueling the need for advanced therapies, including targeted drugs, immunotherapies, and novel treatment modalities like tumor treating fields (TTFields). Furthermore, ongoing clinical trials and regulatory approvals for new GBM treatments reflect the urgent demand to address this aggressive cancer. As more patients seek personalized and effective treatment solutions, the expanding prevalence of GBM will continue to be a key driver propelling market growth globally..
Restraint: Limited Treatment Efficacy and High Recurrence
Limited treatment efficacy and high recurrence rates are significant challenges expected to hinder the growth of the glioblastoma multiforme (GBM) market. Despite advances in surgery, chemotherapy, and radiation, GBM remains one of the most aggressive and treatment-resistant brain cancers, with standard therapies often providing only modest survival benefits. The tumor’s highly invasive nature and ability to develop resistance lead to frequent recurrences, making long-term disease management difficult. This results in high unmet medical needs and patient mortality, which can discourage investment and slow market expansion.
Segmentation Analysis
The glioblastoma multiforme market is segmented by treatment type, drugs, end-user, and region.
Treatment Type-The radiation therapy segment is estimated to have 39.7% of the glioblastoma multiforme market share.
Radiation therapy remains a cornerstone in the treatment of glioblastoma multiforme, serving as the dominant segment in the market due to its established efficacy in managing this aggressive brain cancer. Standard treatment typically involves surgical resection followed by adjuvant radiation therapy to target residual tumor cells. Recent advancements have enhanced the precision and effectiveness of radiation therapy. For instance, the integration of nanomedicine with proton and X-ray radiotherapy has shown promise in improving dose precision and radiosensitization, potentially overcoming the challenges posed by the blood-brain barrier and tumor microenvironment.
Additionally, the development of predictive digital twins for optimizing patient-specific radiotherapy regimens under uncertainty has been proposed, aiming to personalize treatment plans and improve outcomes. These innovations underscore the continued relevance and advancement of radiation therapy in the GBM treatment landscape.
Geographical Shares
The North America glioblastoma multiforme market was valued at 37.20% market share in 2024
North America holds a commanding position in the global glioblastoma multiforme (GBM) market, accounting for approximately 37.2% of the market share in 2024. This leadership is driven by several critical factors, including a robust and well-established healthcare infrastructure, widespread access to cutting-edge diagnostic and therapeutic technologies, and significant investments in research and development. The high incidence rate of GBM in the region further fuels demand for innovative treatments.
Moreover, government initiatives, such as the U.S. Department of Defense’s Glioblastoma Research Program (GBMRP), which received over $10 million in funding in 2024, have accelerated the development of new therapies. The region also benefits from a high concentration of pharmaceutical and biotech companies conducting advanced clinical trials, such as Gilead Sciences’ promising CAR-T cell therapy trials for recurrent GBM, which have demonstrated encouraging tumor response rates. These combined factors create a conducive environment for the rapid adoption of novel therapies, ensuring North America maintains its dominant market position through the forecast period.
The Asia-Pacific glioblastoma multiforme market was valued at 18.60% market share in 2024
The Asia-Pacific region is emerging as the fastest-growing market for glioblastoma multiforme treatments. This growth is driven by multiple factors, including rising incidence rates of GBM in populous countries such as China and India, expanding healthcare infrastructure, and increasing awareness of brain cancers among healthcare providers and patients.
Asia-Pacific has seen an upsurge in international collaborations for clinical research, accelerating the development and approval of innovative therapies tailored to the region’s diverse population. Enhanced diagnostic capabilities and growing adoption of advanced treatment modalities, including immunotherapies and targeted therapies, further fuel the region’s rapid market expansion. These dynamics collectively position Asia-Pacific as a critical growth driver in the global GBM market landscape.
Competitive Landscape
The major players in the glioblastoma multiforme market include Genentech (Roche), Pfizer Inc., Amgen Inc., Merck & Co., Inc., VBI Vaccines Inc. and Starlight Therapeutics, among others.
Genentech: Genentech is a prominent leader in the glioblastoma multiforme market, renowned for its innovative approach to developing targeted therapies and immuno-oncology treatments. The company’s flagship product, Avastin (bevacizumab), is widely used for managing GBM by inhibiting tumor blood vessel growth, helping to slow disease progression. Genentech continuously invests in advanced research and clinical trials to enhance treatment efficacy and explore combination therapies, reinforcing its position as a key player in the GBM market. Their commitment to cutting-edge science and patient-centric solutions ensures sustained growth and a strong global presence in the fight against glioblastoma.
Key Developments:
- In August 2025, Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc., announced that the U.S. Food and Drug Administration (FDA) had granted clearance for its Investigational New Drug (IND) application. This approval enables the initiation of a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for the treatment of patients with glioblastoma multiforme (GBM) at first progression.
- In June 2023, Chimeric Therapeutics announced the initiation of a Phase 1B clinical trial for patients with recurrent and/or progressive glioblastoma multiforme (GBM). The trial will evaluate the safety and efficacy of CHM 1101, Chimeric’s first-in-class CLTX CAR T cell therapy, marking a significant step forward in the development of novel cell-based treatments for aggressive brain cancers.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Treatment Type
2.4. Snippet by Drugs
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Awareness of Reproductive Health
3.1.1.2. Growing Preference for At-Home Testing
3.1.2. Restraints
3.1.2.1. False Positives/Negatives and Test Accuracy Concerns
3.1.2.2. Competition from Clinical Testing
3.1.3. Opportunity
3.1.3.1. Product Innovation and Diversification
3.1.3.2. Emerging Markets Expansion
3.1.4. Impact Analysis
4. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY TREATMENT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
5.1.2. Market Attractiveness Index, By Treatment Type
5.2. Radiation Therapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Chemotherapy
5.4. Immunotherapy
5.5. Surgery
5.6. Others
6. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY DRUGS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
6.1.2. Market Attractiveness Index, By Drugs
6.2. Temozolomide*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lomustine
6.4. Bevacizumab
6.5. Others
7. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Genentech USA, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Pfizer Inc.
10.3. Amgen Inc.
10.4. Merck & Co., Inc.
10.5. F. Hoffmann-La Roche Ltd
10.6. VBI Vaccines Inc.
10.7. Starlight Therapeutics (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Treatment Type
2.4. Snippet by Drugs
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Awareness of Reproductive Health
3.1.1.2. Growing Preference for At-Home Testing
3.1.2. Restraints
3.1.2.1. False Positives/Negatives and Test Accuracy Concerns
3.1.2.2. Competition from Clinical Testing
3.1.3. Opportunity
3.1.3.1. Product Innovation and Diversification
3.1.3.2. Emerging Markets Expansion
3.1.4. Impact Analysis
4. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY TREATMENT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
5.1.2. Market Attractiveness Index, By Treatment Type
5.2. Radiation Therapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Chemotherapy
5.4. Immunotherapy
5.5. Surgery
5.6. Others
6. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY DRUGS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
6.1.2. Market Attractiveness Index, By Drugs
6.2. Temozolomide*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lomustine
6.4. Bevacizumab
6.5. Others
7. GLOBAL GLIOBLASTOMA MULTIFORME MARKET: BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Genentech USA, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Pfizer Inc.
10.3. Amgen Inc.
10.4. Merck & Co., Inc.
10.5. F. Hoffmann-La Roche Ltd
10.6. VBI Vaccines Inc.
10.7. Starlight Therapeutics (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Glioblastoma Multiforme Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Glioblastoma Multiforme Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Glioblastoma Multiforme Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Glioblastoma Multiforme Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Glioblastoma Multiforme Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Glioblastoma Multiforme Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 10 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 12 Global Glioblastoma Multiforme Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Glioblastoma Multiforme Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Glioblastoma Multiforme Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 18 North America Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 19 North America Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Europe Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 28 Europe Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 29 Europe Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 33 South America Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 34 South America Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Abbott : Overview
Table 42 Abbott : Product Portfolio
Table 43 Abbott : Key Developments
Table 44 BIOM?RIEUX: Overview
Table 45 BIOM?RIEUX: Product Portfolio
Table 46 BIOM?RIEUX: Key Developments
Table 47 EKF Diagnostics Holdings plc: Overview
Table 48 EKF Diagnostics Holdings plc: Product Portfolio
Table 49 EKF Diagnostics Holdings plc: Key Developments
Table 50 Atlas Medical GmbH: Overview
Table 51 Atlas Medical GmbH: Product Portfolio
Table 52 Atlas Medical GmbH: Key Developments
Table 53 QuidelOrtho Corporation: Overview
Table 54 QuidelOrtho Corporation: Product Portfolio
Table 55 QuidelOrtho Corporation: Key Developments
Table 56 Biosynex SA: Overview
Table 57 Biosynex SA: Product Portfolio
Table 58 Biosynex SA: Key Developments
Table 59 NG Biotech: Overview
Table 60 NG Biotech: Product Portfolio
Table 61 NG Biotech: Key Developments
Table 62 Cardinal Health: Overview
Table 63 Cardinal Health: Product Portfolio
Table 64 Cardinal Health: Key Developments
Table 65 Thermo Fisher Scientific Inc.: Overview
Table 66 Thermo Fisher Scientific Inc.: Product Portfolio
Table 67 Thermo Fisher Scientific Inc.: Key Developments
Table 68 Procter & Gamble: Overview
Table 69 Procter & Gamble: Product Portfolio
Table 70 Procter & Gamble: Key Developments
Table 1 Global Glioblastoma Multiforme Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Glioblastoma Multiforme Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Glioblastoma Multiforme Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Glioblastoma Multiforme Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Glioblastoma Multiforme Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Glioblastoma Multiforme Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 10 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 12 Global Glioblastoma Multiforme Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Glioblastoma Multiforme Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Glioblastoma Multiforme Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 18 North America Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 19 North America Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Europe Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 28 Europe Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 29 Europe Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 33 South America Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 34 South America Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Glioblastoma Multiforme Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Glioblastoma Multiforme Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Glioblastoma Multiforme Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Glioblastoma Multiforme Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Glioblastoma Multiforme Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Abbott : Overview
Table 42 Abbott : Product Portfolio
Table 43 Abbott : Key Developments
Table 44 BIOM?RIEUX: Overview
Table 45 BIOM?RIEUX: Product Portfolio
Table 46 BIOM?RIEUX: Key Developments
Table 47 EKF Diagnostics Holdings plc: Overview
Table 48 EKF Diagnostics Holdings plc: Product Portfolio
Table 49 EKF Diagnostics Holdings plc: Key Developments
Table 50 Atlas Medical GmbH: Overview
Table 51 Atlas Medical GmbH: Product Portfolio
Table 52 Atlas Medical GmbH: Key Developments
Table 53 QuidelOrtho Corporation: Overview
Table 54 QuidelOrtho Corporation: Product Portfolio
Table 55 QuidelOrtho Corporation: Key Developments
Table 56 Biosynex SA: Overview
Table 57 Biosynex SA: Product Portfolio
Table 58 Biosynex SA: Key Developments
Table 59 NG Biotech: Overview
Table 60 NG Biotech: Product Portfolio
Table 61 NG Biotech: Key Developments
Table 62 Cardinal Health: Overview
Table 63 Cardinal Health: Product Portfolio
Table 64 Cardinal Health: Key Developments
Table 65 Thermo Fisher Scientific Inc.: Overview
Table 66 Thermo Fisher Scientific Inc.: Product Portfolio
Table 67 Thermo Fisher Scientific Inc.: Key Developments
Table 68 Procter & Gamble: Overview
Table 69 Procter & Gamble: Product Portfolio
Table 70 Procter & Gamble: Key Developments
LIST OF FIGURES
Figure 1 Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 4 Global Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Glioblastoma Multiforme Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Line Indicator Kits Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 9 Digital Devices Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 12 hCG Blood Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 13 hCG Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 14 FSH Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 15 LH Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Pharmacies/Drugstores Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 18 Online Sales Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 19 Gynecology/ Fertility Clinics Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 20 Supermarkets Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 21 Hypermarkets Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Glioblastoma Multiforme Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 23 Home Care End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 24 Hospitals End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 25 Others End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 28 North America Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 29 North America Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 30 North America Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 31 North America Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 33 Asia-Pacific Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 34 Asia-Pacific Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 37 Asia-Pacific Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 39 Europe Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 40 Europe Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 Europe Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 42 Europe Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 43 Europe Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Europe Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 46 South America Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 47 South America Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 48 South America Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 49 South America Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 54 Middle East and Africa Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 55 Middle East and Africa Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott : Financials
Figure 57 BIOM?RIEUX: Financials
Figure 58 EKF Diagnostics Holdings plc: Financials
Figure 59 Atlas Medical GmbH: Financials
Figure 60 QuidelOrtho Corporation: Financials
Figure 61 Biosynex SA: Financials
Figure 62 NG Biotech: Financials
Figure 63 Cardinal Health: Financials
Figure 64 Thermo Fisher Scientific Inc.: Financials
Figure 65 Procter & Gamble: Financials
Figure 1 Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 4 Global Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Glioblastoma Multiforme Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Line Indicator Kits Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 9 Digital Devices Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 12 hCG Blood Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 13 hCG Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 14 FSH Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 15 LH Urine Test Test Type in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Pharmacies/Drugstores Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 18 Online Sales Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 19 Gynecology/ Fertility Clinics Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 20 Supermarkets Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 21 Hypermarkets Distribution Channel in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Glioblastoma Multiforme Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 23 Home Care End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 24 Hospitals End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 25 Others End-User in Global Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Glioblastoma Multiforme Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 28 North America Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 29 North America Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 30 North America Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 31 North America Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 33 Asia-Pacific Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 34 Asia-Pacific Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 37 Asia-Pacific Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 39 Europe Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 40 Europe Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 Europe Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 42 Europe Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 43 Europe Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Europe Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 46 South America Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 47 South America Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 48 South America Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 49 South America Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Glioblastoma Multiforme Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Glioblastoma Multiforme Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Glioblastoma Multiforme Market Share, By Product Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Glioblastoma Multiforme Market Share, By Test Type, 2024 & 2033 (%)
Figure 54 Middle East and Africa Glioblastoma Multiforme Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 55 Middle East and Africa Glioblastoma Multiforme Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott : Financials
Figure 57 BIOM?RIEUX: Financials
Figure 58 EKF Diagnostics Holdings plc: Financials
Figure 59 Atlas Medical GmbH: Financials
Figure 60 QuidelOrtho Corporation: Financials
Figure 61 Biosynex SA: Financials
Figure 62 NG Biotech: Financials
Figure 63 Cardinal Health: Financials
Figure 64 Thermo Fisher Scientific Inc.: Financials
Figure 65 Procter & Gamble: Financials
